Nitric oxide nanoparticles

Pre-clinical utility as a therapeutic for intramuscular abscesses

David Schairer, Luis R. Martinez, Karin Blecher Paz, Jason Chouake, Parimala Nacharaju, Philip Gialanella, Joel M. Friedman, Joshua D. Nosanchuk, Adam Friedman

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Nitric oxide (NO) is a critical component of host defense against invading pathogens; however, its therapeutic utility is limited due to a lack of practical delivery systems. Recently, a NO-releasing nanoparticulate platform (NO-np) was shown to have in vitro broad-spectrum antimicrobial activity and in vivo pre-clinical efficacy in a dermal abscess model. To extend these findings, both topical (TP) and intralesional (IL) NO-np administration was evaluated in a MRSA intramuscular murine abscess model and compared with vancomycin. All treatment arms accelerated abscess clearance clinically, histologically, and by microbiological assays on both days 4 and 7 following infection. However, abscesses treated with NO-np via either route demonstrated a more substantial, statistically significant decrease in bacterial survival based on colony forming unit assays and histologically revealed less inflammatory cell infiltration and preserved muscular architecture. These data suggest that the NO-np may be an effective addition to our armament for deep soft tissue infections.

Original languageEnglish (US)
Pages (from-to)62-67
Number of pages6
JournalVirulence
Volume3
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Nanoparticles
Abscess
Nitric Oxide
Colony-Forming Units Assay
Therapeutics
Soft Tissue Infections
Vancomycin
Methicillin-Resistant Staphylococcus aureus
Skin
Infection

Keywords

  • MRSA
  • Nanotechnology
  • Nitric oxide
  • Pyomyositis

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology
  • Parasitology
  • Immunology
  • Microbiology (medical)

Cite this

Nitric oxide nanoparticles : Pre-clinical utility as a therapeutic for intramuscular abscesses. / Schairer, David; Martinez, Luis R.; Blecher Paz, Karin; Chouake, Jason; Nacharaju, Parimala; Gialanella, Philip; Friedman, Joel M.; Nosanchuk, Joshua D.; Friedman, Adam.

In: Virulence, Vol. 3, No. 1, 01.2012, p. 62-67.

Research output: Contribution to journalArticle

@article{375f3f3604764e138bec3f32c1baf8b4,
title = "Nitric oxide nanoparticles: Pre-clinical utility as a therapeutic for intramuscular abscesses",
abstract = "Nitric oxide (NO) is a critical component of host defense against invading pathogens; however, its therapeutic utility is limited due to a lack of practical delivery systems. Recently, a NO-releasing nanoparticulate platform (NO-np) was shown to have in vitro broad-spectrum antimicrobial activity and in vivo pre-clinical efficacy in a dermal abscess model. To extend these findings, both topical (TP) and intralesional (IL) NO-np administration was evaluated in a MRSA intramuscular murine abscess model and compared with vancomycin. All treatment arms accelerated abscess clearance clinically, histologically, and by microbiological assays on both days 4 and 7 following infection. However, abscesses treated with NO-np via either route demonstrated a more substantial, statistically significant decrease in bacterial survival based on colony forming unit assays and histologically revealed less inflammatory cell infiltration and preserved muscular architecture. These data suggest that the NO-np may be an effective addition to our armament for deep soft tissue infections.",
keywords = "MRSA, Nanotechnology, Nitric oxide, Pyomyositis",
author = "David Schairer and Martinez, {Luis R.} and {Blecher Paz}, Karin and Jason Chouake and Parimala Nacharaju and Philip Gialanella and Friedman, {Joel M.} and Nosanchuk, {Joshua D.} and Adam Friedman",
year = "2012",
month = "1",
doi = "10.4161/viru.3.1.18816",
language = "English (US)",
volume = "3",
pages = "62--67",
journal = "Virulence",
issn = "2150-5594",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Nitric oxide nanoparticles

T2 - Pre-clinical utility as a therapeutic for intramuscular abscesses

AU - Schairer, David

AU - Martinez, Luis R.

AU - Blecher Paz, Karin

AU - Chouake, Jason

AU - Nacharaju, Parimala

AU - Gialanella, Philip

AU - Friedman, Joel M.

AU - Nosanchuk, Joshua D.

AU - Friedman, Adam

PY - 2012/1

Y1 - 2012/1

N2 - Nitric oxide (NO) is a critical component of host defense against invading pathogens; however, its therapeutic utility is limited due to a lack of practical delivery systems. Recently, a NO-releasing nanoparticulate platform (NO-np) was shown to have in vitro broad-spectrum antimicrobial activity and in vivo pre-clinical efficacy in a dermal abscess model. To extend these findings, both topical (TP) and intralesional (IL) NO-np administration was evaluated in a MRSA intramuscular murine abscess model and compared with vancomycin. All treatment arms accelerated abscess clearance clinically, histologically, and by microbiological assays on both days 4 and 7 following infection. However, abscesses treated with NO-np via either route demonstrated a more substantial, statistically significant decrease in bacterial survival based on colony forming unit assays and histologically revealed less inflammatory cell infiltration and preserved muscular architecture. These data suggest that the NO-np may be an effective addition to our armament for deep soft tissue infections.

AB - Nitric oxide (NO) is a critical component of host defense against invading pathogens; however, its therapeutic utility is limited due to a lack of practical delivery systems. Recently, a NO-releasing nanoparticulate platform (NO-np) was shown to have in vitro broad-spectrum antimicrobial activity and in vivo pre-clinical efficacy in a dermal abscess model. To extend these findings, both topical (TP) and intralesional (IL) NO-np administration was evaluated in a MRSA intramuscular murine abscess model and compared with vancomycin. All treatment arms accelerated abscess clearance clinically, histologically, and by microbiological assays on both days 4 and 7 following infection. However, abscesses treated with NO-np via either route demonstrated a more substantial, statistically significant decrease in bacterial survival based on colony forming unit assays and histologically revealed less inflammatory cell infiltration and preserved muscular architecture. These data suggest that the NO-np may be an effective addition to our armament for deep soft tissue infections.

KW - MRSA

KW - Nanotechnology

KW - Nitric oxide

KW - Pyomyositis

UR - http://www.scopus.com/inward/record.url?scp=84858229896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858229896&partnerID=8YFLogxK

U2 - 10.4161/viru.3.1.18816

DO - 10.4161/viru.3.1.18816

M3 - Article

VL - 3

SP - 62

EP - 67

JO - Virulence

JF - Virulence

SN - 2150-5594

IS - 1

ER -